Abstract
In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as well as the clinical efficacy and safety of alfuzosin, doxazosin (Cardura®), tamsulosin (Flomax®), and terazosin (Hytrin®) are compared. In reviewing efficacy and safety, emphasis is given to 17 placebo-controlled, double-blind trials of these alpha-blockers published in peer-reviewed journals. This review also considers long-term data, effects on blood pressure, costs, and dose ranges.
Original language | English (US) |
---|---|
Pages (from-to) | 110-119 |
Number of pages | 10 |
Journal | Prostate Cancer and Prostatic Diseases |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - May 1999 |
Externally published | Yes |
Keywords
- Alfuzosin
- Benign prostatic hyperplasia
- Doxazosin
- Tamsulosin
- Terazosin
ASJC Scopus subject areas
- Oncology
- Urology
- Cancer Research